Low concentrations of cerebrospinal fluid GABA correlate to a reduced response to phenobarbital therapy in primary canine epilepsy.
In this study, we investigated whether pretreatment cerebrospinal fluid (CSF) neurotransmitter concentrations of gamma-aminobutyric acid (GABA) and glutamate (GLU) were correlated with response to phenobarbital treatment in dogs with primary epilepsy. Eleven untreated dogs, 6 males and 5 females, with a median age of onset of seizures of 3 years (range: 0.5-5 years) were selected for therapy based on progressive or serious seizure patterns. The median interval between the first observed seizure and start of phenobarbital therapy was 485 days (range: 101-1,765 days). All dogs were purebred, with the exception of I male dog. Oral phenobarbital was started at 2.5 mg/kg every 12 hours. Trough serum phenobarbital concentrations were measured at 15, 45, 90, 180, 360, 540, and 720 days after the start of treatment. There was no difference in the mean trough serum concentration or in the mean number of seizures recorded between each time period of phenobarbital measurement over the 2-year evaluation. No correlation was found between CSF GLU, GABA, or GLU: GABA ratio and the total number of seizures recorded before or after initiation of phenobarbital therapy. Lower CSF GABA concentration, however, was correlated with a lower seizure frequency difference (the total number of seizures before phenobarbital therapy minus the total number of seizures after phenobarbital therapy for an identical time period of evaluation) and lower percentage reduction in seizures: ([total number of seizures before phenobarbital therapy minus the total number of seizures after phenobarbital therapy] divided by the total number of seizures before phenobarbital therapy) x 100. There was no correlation between CSF GLU and the seizure frequency difference and percentage reduction in seizures. A negative correlation between the CSF GLU:GABA ratio and seizure frequency difference was found. Thus, dogs with an initial lower CSF GABA concentration before phenobarbital therapy did not respond as well as did dogs with a higher CSF GABA concentration.
Podell
M
M
Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Ohio State University, Columbus 43210, USA. podell.1@osu.edu
Hadjiconstantinou
M
M
D000818:Animals; D000927:Anticonvulsants / Q000097:blood / Q000627:therapeutic use*; D004283:Dog Diseases / Q000097:blood / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D004285:Dogs; D004827:Epilepsy / Q000188:drug therapy / Q000662:veterinary*; D005260:Female; D018698:Glutamic Acid / Q000134:cerebrospinal fluid; D008297:Male; D010634:Phenobarbital / Q000097:blood / Q000627:therapeutic use*; D012640:Seizures / Q000662:veterinary; D005680:gamma-Aminobutyric Acid / Q000134:cerebrospinal fluid*
D000927:Anticonvulsants; D018698:Glutamic Acid; D005680:gamma-Aminobutyric Acid; D010634:Phenobarbital